Pharmaceutical intermediates
Alectinib Hydrochloride Intermediates
6 pharmaceutical intermediates for Alectinib Hydrochloride. Indication: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms.
About Alectinib Hydrochloride
- Originator
- Chugai Pharmaceutical Co., Ltd
- Indication
- Carcinoma, Non-Small-Cell Lung; Lung Neoplasms
- Approved Date
- 12/11/2015
- DS/DP
- 05/29/2031
Available intermediates
6 intermediates currently listed for Alectinib Hydrochloride. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-(4-ethyl-3-iodophenyl)-2-Methylpropanoic acid | 1256584-73-2 | / | / |
| tert-butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate | 1256584-75-4 | / | / |
| tert-butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan -2-yl)-1Hindole-3-carboxylate | 1256584-75-4 | / | / |
| 2-(4-ethyl-3-iodophenyl)-2-Methylpropanoic acid | 1256584-73-2 | / | / |
| tert-butyl 4-(4-ethyl-3-iodophenyl)-4-methyl-3-oxopentanoate | 1256584-74-3 | / | / |
| 4-(piperidin-4-yl)morpholine | 53617-35-9 | / | / |
Building toward Alectinib Hydrochloride?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →